PMSF, a nerve agent, is used to manufacture HPV vaccines, but it is not supposed to be in the final product. However, new research documents its presence in Merck’s Gardasil and Gardasil 9 HPV vaccines.
By Emily Tarsell
A new peer-reviewed study, “The Expanding Cocktail of Harmful Ingredients in Human Papillomavirus Vaccines,” by Brawer, A.E. and Sullivan, D.H., documents the presence of undisclosed, highly toxic volatile organic chemicals called AEBSF (aminoethyl benzenesulfonyl fluoride) and PMSF (phenylmethylsulfonyl fluoride) in Merck’s two HPV vaccines — Gardasil and Gardasil 9.
PMSF, also known as toluene, is a serine protease/acetylcholinesterase inhibitor, which means it can act as a nerve agent to inactivate central nervous system functions. When PMSF blocks the enzyme acetylcholinesterase, the result can be uncontrollable firing of motor signals which can manifest as seizures or other biochemical or physiological disorders. PMSF has been used as a nerve agent in biological warfare.
PMSF and AEBSF are used to manufacture HPV vaccines, but are not supposed to be in the final product and therefore do not have to be listed as ingredients.
However, this new study documents that these toxic organic chemicals are in the final vaccine product and likely initiate the onset of a host of serious adverse events that have been reported following HPV inoculations.
Such outcomes include cardiovascular events, motor neuron disorders, autoimmune disorders, cognitive and mood disorders, neurological disorders, gastrointestinal disorders, miscarriages, menstrual disorders, seizures, headaches, extreme fatigue, skin disorders, sleep disorders, paralysis, encephalitis — and even sudden death.
Since these toxic chemicals are not publicly disclosed and are not listed in the package insert, how was it discovered that they are used in the manufacturing process and that they are, in fact, in the final product?
It was first discovered by a mother, Elizabeth O. Schneider, whose son, John, suffered severe adverse reactions as an infant after receiving the Hepatitis B vaccine, Engerix B, in 1993. Schneider was driven to find out what happened to her infant son.
In 1995, Schneider used the Freedom of Information Act to obtain a transcript of the 1988 U.S. Food and Drug Administration (FDA) Advisory Committee meeting at which the Engerix hepatitis B vaccine was approved. Though a lot of information in the transcript was redacted, the identity and use of PMSF was not — prompting Schneider to find out more about the chemical.